UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of ~~May~~July 2025

Commission File Number: 001-41773

Adlai Nortye Ltd.

c/o PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands

Grand Cayman, KY1-1104

Cayman Islands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F   ☐ Form 40-F

CONTENT

~~Announcement~~Adoption of ~~Topline~~2025 ~~Results~~Share ofIncentive ~~Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC~~Plan

On July 1, 2025, the Board of Directors (“Board”) of Adlai Nortye Ltd. (the “Company”) orapproved ~~“Adlai~~and ~~Nortye”) announced~~authorized ~~topline~~the ~~results~~adoption ~~from~~of ~~its~~the ~~Phase~~2025 ~~III~~Share ~~BURAN~~Incentive ~~trial~~Plan, ~~evaluating~~effective ~~buparlisib~~on the same date (~~AN2025~~the “Plan”),. aUnder ~~PI3K~~the ~~inhibitor~~Plan, inthe ~~combination~~Company ~~with~~will ~~paclitaxel for~~be ~~the~~permitted ~~treatment~~to ofgrant ~~patients~~awards ~~with~~of ~~recurrent~~options, orrestricted ~~metastatic~~shares, ~~head~~restricted share units and ~~neck~~other ~~squamous~~types ~~cell~~of ~~carcinoma~~awards as the case may require (~~HNSCC~~the “Awards”).

The ~~study~~purposes ~~did~~of ~~not~~the ~~meet~~Plan are to attract and retain the ~~primary~~best ~~endpoint~~available personnel for positions of ~~improving~~substantial ~~overall~~responsibility, ~~survival compared~~to provide additional incentives to ~~paclitaxel~~selected ~~alone.~~employees, directors, ~~The~~and ~~safety~~consultants ~~profile~~and ofto ~~buparlisib~~promote ~~was~~the ~~consistent~~success ~~with~~of ~~previous~~the ~~findings,~~Company’s ~~with~~business noby ~~new~~offering ~~safety~~these ~~signals~~individuals ~~observed.~~an opportunity to ~~Detailed~~acquire ~~results~~a ~~will~~proprietary beinterest ~~presented~~in atthe ansuccess ~~upcoming~~of ~~medical~~the ~~conference~~Company, or to increase this interest by permitting them to acquire shares of the Company.

~~“We~~The ~~are~~Plan ~~disappointed~~shall ~~with~~be ~~the~~administered ~~outcome~~by of the ~~phase III BURAN~~Board ~~study,”~~of ~~said~~the ~~Carsten~~Company. ~~Lu,~~The ~~CEO~~Board ~~and Chairman~~ of ~~Adlai Nortye. “While~~ the ~~outcome~~Company ismay ~~not~~authorize ~~what~~one weor ~~hoped~~more ~~for,~~committees weor ~~are~~officers ~~deeply grateful~~ to administrate the ~~patients,~~grants ~~investigators,~~of ~~and~~any ~~research~~Awards ~~teams whose commitment~~ and ~~contributions made this global trial possible. Based on these~~ ~~results,~~may welimit ~~have~~such ~~decided~~authority toas ~~discontinue further development of buparlisib. We will, however, continue to analyze~~ the ~~data~~Board todetermines ~~better~~from ~~understand the~~time ~~findings and~~ to ~~inform future drug development in HNSCC~~time.”

“The ~~Company expects to make near-~~term ~~changes~~of tothe ~~its~~Plan ~~business operations~~is ~~and~~ten toyears ~~reduce~~from ~~its workforce in order to preserve cash, including but not limited to: optimizing workforce structure and compensation,~~the ~~pursuing~~date ~~strategic~~of ~~business development opportunities~~adoption, ~~and~~unless ~~expanding~~sooner ~~our~~terminated ~~financing~~according ~~options,” Carsten Lu added. “We will refocus our resources and efforts on advancing AN8025 and AN9025, together with our emerging candidates, which we believe have strong potential~~ to ~~address~~the ~~unmet~~terms ~~needs~~of ~~across~~the ~~multiple tumor types, and deliver transformative therapies to patients worldwide~~Plan.”

~~About~~Resignation ~~Phase~~of ~~III~~Independent ~~BURAN Trial~~Director

~~The~~In ~~BURAN~~June ~~study is a randomized (2:1)~~2025, ~~open-label Phase III study to assess~~ the ~~treatment~~Board ~~effect~~ of ~~buparlisib~~the inCompany ~~combination~~received ~~with~~the ~~paclitaxel compared to weekly paclitaxel alone in patients with recurrent~~resignation ~~and~~of ~~metastatic~~Dr. ~~HNSCC~~Cheguo ~~that~~Cai ~~have progressed after anti-PD-~~(~~L)1-based treatment~~“Dr. ACai”) ~~total~~from ofhis ~~487~~positions ~~patients~~as ~~were~~an ~~enrolled~~independent ~~globally.~~Director ~~The primary endpoint~~ of the ~~trial~~Company ~~was~~and ~~overall~~a ~~survival~~member ~~(OS),~~of ~~with~~each ~~secondary~~of ~~endpoints~~the audit ~~including~~committee, ~~progression-free~~compensation ~~survival (PFS)~~committee, ~~objective~~and ~~response rate~~nominating ~~(ORR),~~ and ~~duration~~corporate ofgovernance ~~response~~committee ~~(DoR).~~of ~~This~~the ~~Phase~~Board ~~III~~(respectively, ~~trial~~the “Audit ~~builds~~Committee”, on“Compensation ~~positive~~Committee” ~~Phase~~and II“NCG ~~data~~Committee”, ~~where~~together, the “Committees”), ~~buparlisib-paclitaxel~~with ~~combination demonstrated~~effect ~~improvements~~from inJuly ~~ORR~~1, ~~PFS,~~2025. ~~and~~Dr. OSCai ~~compared~~resigned due to ~~paclitaxel~~personal ~~alone.~~reasons ~~Notably,~~and ~~these~~not ~~Phase~~as IIthe ~~findings~~result ~~preceded~~of ~~the establishment~~any ofdispute ~~anti-PD-(L)1~~or ~~therapies~~disagreement aswith the ~~cornerstone~~Company ~~treatment~~or ~~for~~the ~~recurrent/metastatic HNSCC~~Board.

~~About~~Appointment ~~AN8025~~of Replacement Director

~~AN8025~~Effective isJuly ~~a next-generation tri-specific~~1, ~~antibody~~2025, ~~fusion~~the ~~protein~~Board inof ~~particular~~the ~~PD-1-based~~Company ~~immunotherapy,~~appointed ~~derived~~Mr. ~~from~~Baozhong anWei ~~approved~~(“Mr. ~~αPD-L1~~Wei”) ~~antibody~~as ~~and~~an ~~fused~~independent ~~with~~Director ~~functionally~~as ~~optimized~~well ~~CD86~~as ~~and~~the ~~LAG3~~chairman ~~variants.~~of ~~Designed~~the toCompensation ~~modulate~~Committee T(following ~~cell~~the ~~and~~Change ~~antigen-presenting~~in ~~cell~~Compensation ~~(APC)~~Committee ~~functions~~Composition, ~~preclinical~~as ~~studies~~defined ~~have~~below). ~~demonstrated~~The ~~that~~Board ~~AN8025~~of ~~enhances both~~ the ~~quantity~~Company ~~and~~has ~~quality~~received ofMr. ~~APCs~~Wei’s ~~while~~consent ~~also~~to ~~inducing robust~~act ~~PD-L1-dependent~~as Tan ~~cell~~independent Director ~~activation~~ and ~~anti-tumor~~determined ~~efficacy~~that ~~in vivo~~Mr. ~~The~~Wei ~~Company~~meets ~~plans to submit~~ the ~~IND~~Nasdaq ~~application~~Stock inMarket ~~mid-2025~~independence requirements.

~~About~~Mr. ~~AN9025~~Wei Baozhong, aged 47, is an accomplished financial professional with over 19 years of experience in corporate governance, financial reporting, and regulatory compliance. Since November 2017, Mr. Wei has served as a director of BR Business Services Pte Ltd, where he oversees business operations and provides strategic guidance.

AN9025 is an in-house developed oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, designed to target a broad spectrum of RAS mutations across various tumor types. Preclinical studies have demonstrated that AN9025 effectively inhibits RAS-mutant cancers with potent and durable efficacy, including pancreatic, lung, and colorectal adenocarcinomas, and shows comparable or superior results relative to a benchmark agent of the same class. The company plans to submit an IND application in the second half of 2025.

About AN4005

AN4005 is an orally available, small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction. Preliminary results from the Dose-Escalation Phase, presented at SITC 2024, demonstrated that AN4005 exhibits favorable safety and tolerability in patients with advanced tumors. Encouraging preliminary efficacy was observed in a tumor type known to respond to anti-PD-(L)1 therapy. The trial has now advanced to the Expansion Phase, evaluating two doses of AN4005 in checkpoint inhibitor-naïve patients. Proof-of-concept data from the Expansion Phase is expected by the end of 2025.

~~About~~Mr. ~~Adlai~~Wei ~~Nortye~~brings extensive expertise in corporate finance and advisory services. From August 2015 to October 2017, he served as an assistant manager at BDO Advisory Pte Ltd, where he specialized in corporate finance, valuation, financial due diligence, litigation support, and merger and acquisition activities. Prior to that, from June 2014 to July 2015, he was a finance manager at JES International Holdings Limited, where he handled full sets of company accounts, group consolidation, cash flow reporting, and assisted with audit procedures and tax filings. From November 2012 to June 2014, Mr. Wei worked as an assistant manager at MS Corporate Finance Pte Ltd, focusing on corporate finance assignments including company valuations and independent financial adviser services.

~~Adlai~~Mr. ~~Nortye~~Wei is a Chartered Accountant (~~NASDAQ:~~Singapore) ~~ANL~~and an Accredited Tax Advisor (Corporate Tax and GST). He is aalso ~~global~~an ~~clinical~~ACRA-~~stage~~registered ~~company~~Corporate ~~focused on~~Services ~~the~~Provider ~~development~~and ofqualified ~~innovative~~Filing ~~cancer~~Agent. ~~therapies,~~Mr. ~~with~~Wei ~~global~~holds ~~R&D~~a Master's ~~centers~~degree in ~~the~~Finance ~~U.S.~~from Singapore Management University and ~~China,~~a ~~the~~Bachelor's ~~Company~~degree isin ~~advancing~~Accountancy afrom ~~robust oncology~~Oxford ~~pipeline~~Brookes University. His Wecomprehensive ~~are~~experience ~~advancing~~in ~~multiple~~cross-border ~~drug~~structuring, ~~candidates~~mergers ~~including~~and ~~AN8025~~acquisitions, aand ~~multifunctional~~risk ~~fusion~~management, ~~protein~~combined ~~acting~~with ashis ahands-on Texperience working ~~cell~~alongside boards and ~~antigen-presenting~~ ~~cell~~audit ~~(“APC”) modulator~~committees, ~~AN9025,~~provides anvaluable ~~oral~~financial ~~small~~expertise ~~molecule~~and ~~pan-RAS(ON)~~strategic ~~inhibitor,~~insight ~~and~~that ~~AN4005,~~align anwell ~~oral~~with ~~small~~the Company’s ~~molecule~~corporate ~~PD-L1~~governance ~~inhibitor~~requirements.

~~Forward-Looking~~Mr. ~~Statement~~Wei has no family relationships with any other executive officers or Directors of the Company.

~~This~~There ~~announcement~~is ~~contains~~no ~~forward-looking~~arrangement ~~statements.~~or ~~These~~understanding ~~statements are~~between ~~made under the “safe harbor” provisions of the U~~Mr.S. ~~Private~~Wei Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and ~~similar~~any ~~statements. Among~~ other ~~things, statements that are not historical facts, including~~ ~~statements~~person ~~about~~pursuant ~~the~~to ~~Company’s~~which ~~beliefs~~he ~~and~~was ~~expectations,~~selected ~~the business outlook and quotations from management in this announcement,~~ as ~~well~~a asDirector of the Company~~’s strategic and operational plans, are or contain forward-looking statements~~.

~~The~~There ~~Company~~is ~~may~~no ~~also~~transaction ~~make written or oral forward-looking statements~~ in ~~its~~which ~~periodic reports to the U~~Mr.S. ~~Securities~~Wei ~~and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors~~ or ~~employees~~any to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of ~~the~~his ~~Company’s~~immediate ~~preclinical~~family ~~studies,~~members ~~clinical~~has ~~trials~~an ~~and~~interest ~~other~~requiring ~~therapeutic~~disclosure ~~candidate~~under ~~development~~Item 404(a) efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of ~~real-world~~Regulation results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forwardS-~~looking statement, except as required under applicable law~~K.

Re-designation of Director

Effective July 1, 2025, the Board of the Company re-designated Dr. Roger Sawhney (“Dr. Sawhney”) from a Director to an independent Director, and appointed Dr. Sawhney as a member of each of the Audit Committee and NCG Committee.

The Board of the Company has received Dr. Sawhney’s consent to act as an independent Director and determined that Dr. Sawhney meets the Nasdaq Stock Market independence requirements.

Change of Committee Members

Effective July 1, 2025, the Board of the Company approved Mr. Yang Lu’s resignation as the chairman of the Compensation Committee (“Change in Compensation Committee Composition”).

In view of the resignation of Dr. Cheguo Cai, the Board of the Company appointed Mr. Alan Ming Lun Tse as a member of the Compensation Committee, effective from July 1, 2025.

Following the abovementioned Resignation of Independent Director, Appointment of Replacement Director, Re-designation of Director and Change of Committee Members, the members of the Committees are as follows:

	Audit Committee	Compensation Committee	NCG Committee
Chairman	Alan Ming Lun Tse	Baozhong Wei	Yang Lu
Member	Roger Sawhney	Alan Ming Lun Tse	Roger Sawhney
Member	Shaorong Liu	Shaorong Liu	Shaorong Liu

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Adlai Nortye Ltd.

	By:	/s/ Yang Lu
	Name:	Yang Lu
	Title:	Chief Executive Officer and Chairman of Board of Directors

Date: ~~May~~July 309, 2025

Filing Compare · Adlai Nortye Ltd.